Last reviewed · How we verify

DA-9501 — Competitive Intelligence Brief

DA-9501 (DA-9501) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Herbal extract / Hepatoprotective agent. Area: Hepatology / Gastroenterology.

phase 3 Herbal extract / Hepatoprotective agent Hepatology / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

DA-9501 (DA-9501) — Hospira, now a wholly owned subsidiary of Pfizer. DA-9501 is a standardized herbal extract that modulates inflammatory and immune pathways to improve hepatic function and reduce liver injury.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DA-9501 TARGET DA-9501 Hospira, now a wholly owned subsidiary of Pfizer phase 3 Herbal extract / Hepatoprotective agent
Silymarin capsule simulant Silymarin capsule simulant Xinhua Hospital, Shanghai Jiao Tong University School of Medicine marketed Herbal extract / Hepatoprotective agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Herbal extract / Hepatoprotective agent class)

  1. Hospira, now a wholly owned subsidiary of Pfizer · 1 drug in this class
  2. Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DA-9501 — Competitive Intelligence Brief. https://druglandscape.com/ci/da-9501. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: